



# **ASTAL LABORATORIES LIMITED**

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina  
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: <https://astallabs.com/>

---

Date: 30-05-2026

To,  
The Deputy Manager  
(Department of Corporate Services)  
BSE Limited  
P. J. Towers Dalal Street,  
Fort, Mumbai- 400001

**Sub: Revised Audited Standalone and Consolidated Financial Results for the quarter and the year ended 31<sup>st</sup> March, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Ref.: Scrip Code: 512600**

**Security Id: ASTALLTD**

---

Respected Sir/ Madam,

Pursuant to our earlier submission dated 30<sup>th</sup> May, 2026 and the Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), the Board of Directors at their meeting held on 30<sup>th</sup> May, 2026 have considered and approved, the Audited Standalone and Consolidated Financial Results of the company for the quarter and year ended 31<sup>st</sup> March, 2026 along with the report of the auditors thereon. Due to typographical error in our earlier submission we are hereby resubmitting the financial results.

The Auditors' Report with an unmodified opinion on the said financial results is also attached herewith.

The Board Meeting commenced at 05:00 p.m. (IST) and concluded at 07:20 p.m. (IST)

The aforesaid information is also available on the website of the Company <https://astallabs.com>.

We request you to take the aforesaid information on record for dissemination through your website.

Thanking you,

Yours Faithfully,

**For Astal Laboratories Limited**

**Mahendra Kumar**  
(Company Secretary & Compliance Officer)  
Membership No.: A71224

**Independent Auditor's Report on Audited standalone Quarterly Financial Results and Year to Date Results of Astal Laboratories Limited (Formerly Known as Macro International Limited) Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
**The Board of Directors of  
Astal Laboratories Limited  
(Formerly Known as Macro International Limited)**  
Office No. B7, A-40, Sector 4,  
Noida, Gautam Buddha Nagar,  
Uttar Pradesh 201301

**Report on the audit of Standalone Financial Results**

**Opinion**

We have audited the accompanying standalone quarterly financial results of Astal Laboratories Limited (Formerly Known as Macro International Limited) for the quarter ended 31<sup>st</sup> March 2026 and the year ended 31<sup>st</sup> March 2026 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended March 31, 2026 as well as the year ended as on March 31, 2026.



## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## **Management's Responsibilities for the Standalone Financial Results**

The Statement has been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.



## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


### **Other Matter**

- The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review as required under the Listing Regulations.

For Sathuluri & Co.  
Chartered Accountants  
(FRN. No.006383S)



CA S S Prakash  
Partner  
M.No. 202710



UDIN: 26202710JHFIOZ1232

Place: Hyderabad  
Date : 30-05-2026

**Independent Auditor's Report on Audited Consolidated Quarterly Financial Results and Year to Date Results of Astal Laboratories Limited (Formerly Known as Macro International Limited) Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To  
**The Board of Directors of  
Astal Laboratories Limited  
(Formerly Known as Macro International Limited)**  
Office No. B7, A-40, Sector 4,  
Noida, Gautam Buddha Nagar,  
Uttar Pradesh 201301

**Report on the audit of Consolidated Financial Results**

**Opinion**

We have audited the accompanying Statement of Consolidated Financial Results of Astal Laboratories Limited (Formerly Known as Macro International Limited) ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 31<sup>st</sup> March 2026 and the year ended 31<sup>st</sup> March 2026 attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("LODR Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the report of the other auditor on separate audited Ind AS financial statements of the subsidiary, these Consolidated financial statement:

i. includes the results of:

A. Subsidiaries (Direct)

**Sl. No. Name of Entities**

**Country of Incorporation**

1. Sriven Pharmachem India Private Limited India

ii. are presented in accordance with the requirements of Regulation 33 of the LODR Regulations in this regard; and



- iii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information of the Group for the quarter ended March 31, 2026 and for the year ended March 31, 2026.

### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Management's Responsibilities for the Consolidated Financial Results**

The Statement has been prepared on the basis of the Consolidated Annual Financial Statements. The Holding Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standard prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidation financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.



In preparing the statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the Company's ability of their respective companies to continue as a going concern to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the financial reporting process of their respective companies.

### **Auditor's Responsibilities for the Audit of the Consolidated Financial Results**

Our objectives are to obtain reasonable assurance about whether the statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial



results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results / financial information of the Company of which we are the independent auditors and whose financial information we have audited, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of company included in the Statement of which we are the independent auditors. For the other entity included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance the Holding Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence; and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Master Circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

#### **Other Matter**

The accompanying Statement includes the audited financial statements and other financial information, in respect of:

- One Wholly owned subsidiary whose financial statements include total assets of Rs. 19,313.92 Lakhs as at March 31, 2026, total revenue of Rs. 9,418.27 Lakhs and Rs. 9,418.27 Lakhs, total net profit after tax of Rs. 659.40 Lakhs and Rs. 659.40 Lakhs, total comprehensive income of Rs.659.40 lakhs and Rs. 659.40 Lakhs for the quarter ended 31-03-2026 and for the period from 14-01-2026 to 31-03-2026 respectively, and net cash outflows of




Rs. 488.06 Lakhs for the period from 14-01-2026 to 31-03-2026, as considered in the Statement which have been audited by other auditor whose reports have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated in Basis for Opinion paragraph.


The independent auditor's report on the financial statements of subsidiary has been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of this subsidiary is based solely on the report of its auditor and the procedures performed by us as stated in paragraph above.

The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2026 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review as required under the Listing Regulations.

For Sathuluri & Co.  
Chartered Accountants  
(FRN. No.006383S)



CA S S Prakash  
Partner  
M.No. 202710



UDIN: 26202710GPFCS8086

Place: Hyderabad  
Date : 30-05-2026

**Statement of Audited Standalone Financial Results for the quarter and year ended 31<sup>st</sup> March, 2026**

(Rs. In Lakhs except Earning per share)

S. No.	Particulars	3 Months Ended	Preceding 3 Months ended	Corresponding 3 Months Ended in Previous Year	Year to Date Figures for Current Period Ended	Year to date figures for Previous year ended
		31.03.2026 (Audited)	31.12.2025 (Unaudited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
1	<b>Revenue</b>					
	a) From operations	4,091.70	5,223.53	2,346.67	15,599.53	6,423.10
	b) Other Income	6.62	3.65	3.50	19.15	12.51
	<b>Total Revenue</b>	<b>4,098.32</b>	<b>5,227.18</b>	<b>2,350.17</b>	<b>15,618.68</b>	<b>6,435.61</b>
2	<b>Expenses</b>					
	(a) Cost of Material Consumed	3,622.87	5,449.34	2,484.49	15,288.45	6,181.42
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	122.72	(736.62)	(649.20)	(1,401.56)	(1,370.22)
	(d) Employees Benefits expenses	80.72	44.00	9.08	211.26	133.85
	(e) Finance Cost	46.72	33.21	26.58	140.91	70.07
	(f) Depreciation amortization expenses	32.10	12.48	10.41	68.84	22.31
	(g) Other Expenses	46.02	111.67	83.95	224.23	200.42
	<b>Total Expenses</b>	<b>3,951.14</b>	<b>4,914.08</b>	<b>1,965.32</b>	<b>14,532.12</b>	<b>5,237.86</b>
3	Profit from ordinary activities before exceptional Items (1-2)	147.18	313.10	384.85	1,086.56	1,197.75
4	Exceptional Items - Income/ (Expenses)	--	--	--	--	--
5	<b>Profit from ordinary activities before tax (3 - 4)</b>	<b>147.18</b>	<b>313.10</b>	<b>384.85</b>	<b>1,086.56</b>	<b>1,197.75</b>
6	Tax Expenses					
	(a) Current Tax	41.73	81.09	111.48	258.84	294.08
	(b) Deferred Tax	(3.14)	-3.72	(1.10)	16.17	11.14

*[Handwritten Signature]*





**Astal Laboratories Limited**

**ASTAL LABORATORIES LIMITED**

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: <https://astallabs.com/>

7	<b>Profit/(Loss) for the period (5 -6)</b>	<b>108.59</b>	<b>235.73</b>	<b>274.48</b>	<b>811.55</b>	<b>892.53</b>
8	A (i) Items that will not be reclassified to profit or loss (net of tax)	--	--	--	--	--
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	--	--	--	--	--
	B (i) Items that will be reclassified to profit or loss (net of tax)	--	--	--	--	--
	(ii) Income Tax relating to items that will be reclassified to profit or loss	--	--	--	--	--
9	<b>Total Comprehensive Income, net of tax (7 + 8)</b>	<b>108.59</b>	<b>235.73</b>	<b>274.48</b>	<b>811.55</b>	<b>892.53</b>
10	Paid up equity share capital (Face Value of Rs.10/- each)	4223.12	1,078.55	984.56	4223.12	984.56
11	Earning per share (of Rs.10/-each)					
	(a) Basic	<b>0.288</b>	<b>2.189</b>	<b>2.802</b>	<b>4.757</b>	<b>9.080</b>
	(b) Diluted	<b>0.275</b>	<b>1.738</b>	<b>1.765</b>	<b>4.310</b>	<b>8.043</b>
<b>See accompanying notes to Audited standalone financial results:</b>						

Place: Hyderabad

Date: 30/05/2026



//By the order of the Board//  
For Astal Laboratories Limited

**SUDHEER KARNA KANKANALA**  
(Wholetime Director)  
DIN: 07591466



**Astal Laboratories Limited**

# **ASTAL LABORATORIES LIMITED**

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: <https://astallabs.com/>

## **NOTES TO AUDITED STANDALONE FINANCIAL RESULTS:**

1	The above Audited Standalone Financial Results of the company for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 30 <sup>th</sup> May, 2026.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website <a href="https://astallabs.com/">https://astallabs.com/</a>

Place: Hyderabad  
Date: 30/05/2026

//By the order of the Board//  
For Astal Laboratories Limited




**SUDHEER KARNA KANKANALA**  
(Wholetime Director)  
DIN: 07591466

**STATEMENT OF AUDITED STANDALONE ASSETS AND LIABILITIES AS AT  
MARCH 31, 2026**

(Rs. In lakhs.)

PARTICULARS		As at 31-March 2026	As at 31-March 2025
		(Audited)	(Audited)
<b>ASSETS</b>			
<b>1</b>	<b>Non - current assets</b>		
(a)	Property, plant and equipment	1135.84	1144.43
(b)	Right-of-use-asset	74.85	
(c)	Investment property		
(d)	Intangible assets		
(e)	Financial assets		
	(i) Investment in Sriven Pharmachem India Pvt Ltd	27716.95	
	(ii) Loans	409.26	409.25
	(iii) Balance With Banks	283.74	206.46
(f)	Deferred tax Assets (Net)		
(g)	Other Non-current assets	10.53	10.00
	<b>Total non-current assets</b>	<b>29631.17</b>	<b>1770.15</b>
<b>2</b>	<b>Current assets</b>		
(a)	Inventories	2877.54	1475.98
(b)	<b>Financial assets</b>		
	(i) Investments		
	(ii) Trade receivables	7230.17	2766.41
	(iii) Cash and cash equivalents	69.60	173.00
	(iv) Other balances with banks		
	(v) Loans		
	(vi) Other financial assets	0.00	0.00
(c)	Other Current assests	148.72	148.53
	<b>Total current assets</b>	<b>10326.03</b>	<b>4563.92</b>
	<b>TOTAL ASSETS</b>	<b>39957.20</b>	<b>6334.06</b>
<b>EQUITY AND LIABILITIES</b>			
<b>1</b>	<b>Equity</b>		
(a)	Share capital	4223.12	984.56
(b)	Other equity	28493.20	2614.91
	<b>Total Equity</b>	<b>32716.32</b>	<b>3599.47</b>
<b>2</b>	<b>Non-current liabilities</b>		
(a)	Financial liabilities		
	(i) Long-term borrowings	36.59	45.61
	(ii) Deferred tax liabilities (net)	28.03	11.86
	(iii) Lease Liabilities	64.78	
(b)	Provisions		
(c)	Other Non Current liabilities		

*[Handwritten Signature]*





**Astral Laboratories Limited**

## **ASTAL LABORATORIES LIMITED**

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: <https://astallabs.com/>

	<b>Total non-current liabilities</b>	<b>129.40</b>	<b>57.47</b>
3	<b>Current liabilities</b>		
(a)	Financial liabilities		
	(i) Borrowings	1159.20	1281.21
	(ii) Trade payables	5406.67	1077.49
	(iii) Lease Liabilities	16.21	0.00
(b)	Provisions		
(c)	Other current Liabilities	529.40	318.42
	<b>Total current liabilities</b>	<b>7111.48</b>	<b>2677.12</b>
	<b>Total Liabilities</b>	<b>7240.88</b>	<b>2734.59</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>39957.20</b>	<b>6334.06</b>

Place: Hyderabad

Date: 30/05/2026



//By the order of the Board//

For Astal Laboratories Limited

**SUDHEER KARNA KANKANALA**  
(Wholetime Director)

DIN: 07591466



**Astal Laboratories Limited**

**ASTAL LABORATORIES LIMITED**

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 I Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India


Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

**STATEMENT OF AUDITED STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2026**

(Rs. In Lakhs)

PARTICULARS	2025-26	2024-25
	Amount (Rs.)	Amount (Rs.)
<b>A. CASH FLOW FROM OPERATING ACTIVITIES: -</b>		
Net Profit/(Loss) before tax as per statement of Profit & Loss	1,086.56	1,197.75
Adjustment for:		
Depreciation	68.84	22.31
Finance Cost	140.91	70.07
Interest Income	(19.16)	(12.51)
Operating Profit before working capital changes.	1,277.16	1,277.63
Adjustment for: -		
Changes in Trade Receivables	(4,463.77)	(1,184.90)
Changes in Trade Payables	4,329.18	(74.03)
Changes in Inventory	(1,401.56)	(1,370.22)
Changes in Other Current Assets	(0.19)	229.38
Changes in Other Non Current assets	(0.53)	(10.00)
Changes in Other Current liabilities	54.21	(89.46)
Cash generated form operations	(205.50)	(1,221.60)
Taxes paid (Net)	(102.08)	(30.13)
<b>Net cash generated from / (used in) Operating Activities</b>	<b>(307.57)</b>	<b>(1,251.73)</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES: -</b>		
Interest Income	19.16	12.51
Purchase of Fixed Assets	(40.72)	(577.50)
Investment in Sriven Pharma-Cash Consideration	(29.63)	-
(Issue) / Recovery of Loans and advances	(0.00)	(10.00)
Fixed Deposit with Banks	(77.28)	(206.46)
<b>Net cash from Investing Activities</b>	<b>(128.47)</b>	<b>(781.44)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES: -</b>		
Interest Expense	(131.95)	(70.07)
Interest Expense on Lease Liability	(8.97)	
Principal payment on Lease Liability	(13.38)	
Long Term Borrowings Taken	-	31.67
Long Term Borrowings Repaid	(9.02)	(5.47)
Issue of Shares		-
Security Premium		
Share Warrents Amount received	617.98	372.99
<b>Net cash from (used in) Financing Activities</b>	<b>454.67</b>	<b>329.12</b>
<b>Net (Decrease)/Increase in Cash &amp; Cash Equivalent (A+B+C)</b>	<b>18.62</b>	<b>(1,704.05)</b>
<b>Opening Balance of Cash &amp; Cash Equivalents</b>	<b>(1,096.40)</b>	<b>607.65</b>
Cash on hand	0.02	0.03

*Handwritten signature*



Balance With Banks	172.99	607.61
Bank overdrafts and cash credit facility (secured)*	(1,269.40)	-
<b>Closing Balance of Cash &amp; Cash Equivalents</b>	<b>(1,077.78)</b>	<b>(1,096.40)</b>
Cash on hand	7.60	0.02
Balance With Banks	62.0	172.99
Bank overdrafts and cash credit facility (secured)*	(1,147.4)	(1,269.40)

**Notes to Standalone Audited Cash flow statement**

1. Figures in brackets represent cash out flows.
2. The above Cash Flow statement has been prepared under the "Indirect Method" set out in Accounting Standard (Ind AS-7) on Statement of Cash flows issued by the Institute of Chartered Accountants of India.
3. Previous year's comparative have been reclassified to conform with current year's presentation wherever applicable.
4. Bank overdrafts and cash credit facility are part of cash management system of the Company. Hence, considered as part of cash and cash equivalents

//By the order of the Board//  
For Astal Laboratories Limited

Place: Hyderabad  
Date: 30/05/2026



  
**SUDHEER KARNA KANKANALA**  
(Wholetime Director)  
DIN: 07591466



Astal Laboratories Limited

# ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com; Mob. No: 6302730973, Website: https://astallabs.com/

## Statement of Audited Consolidated Financial Results for the quarter and year ended 31<sup>st</sup> March, 2026

(Rs. In Lakhs except Earning per share)

S. No	Particulars	3 Months Ended	Preceding 3 Months ended	Corresponding 3 Months Ended in Previous Year	Year to Date Figures for Current Period Ended	Year to date figures for Previous year ended
		31.03.2026 (Audited)	31.12.2025 (Unaudited)	31.03.2025 (Audited)	31.03.2026 (Audited)	31.03.2025 (Audited)
1	<b>Revenue</b>					
	a) From operations	13,404.90	5,223.53	2,346.67	24,912.73	6,423.10
	b) Other Income	9.62	3.65	3.50	22.15	12.51
	<b>Total Revenue</b>	<b>13,414.52</b>	<b>5,227.18</b>	<b>2,350.17</b>	<b>24,934.88</b>	<b>6,435.61</b>
2	<b>Expenses</b>					
	(a) Cost of Material Consumed	10,824.99	5,449.34	2,484.49	22,490.57	6,181.42
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	935.71	(736.62)	(649.20)	(588.57)	(1,370.22)
	(d) Employees Benefits expenses	371.61	44.00	9.08	502.15	133.85
	(e) Finance Cost	109.05	33.21	26.58	203.25	70.07
	(f) Depreciation amortization expenses	86.08	12.48	10.41	122.82	22.31
	(g) Other Expenses	253.43	111.67	83.95	431.63	200.42
	<b>Total Expenses</b>	<b>12,580.87</b>	<b>4,914.08</b>	<b>1,965.32</b>	<b>23,161.85</b>	<b>5,237.86</b>
3	Profit from ordinary activities before exceptional Items (1 - 2)	833.65	313.10	384.85	1,773.03	1,197.75
4	Exceptional Items - Income/ (Expenses)	--	--	--	--	--
5	<b>Profit from ordinary activities before tax (3 - 4)</b>	<b>833.65</b>	<b>313.10</b>	<b>384.85</b>	<b>1,773.03</b>	<b>1,197.75</b>
6	<b>Tax Expenses</b>					
	(a) Current Tax	50.93	81.09	111.48	268.04	294.08
	(b) Deferred Tax	14.73	(3.72)	(1.10)	34.05	11.14





**Astal Laboratories Limited**

**ASTAL LABORATORIES LIMITED**

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: <https://astallabs.com/>

7	<b>Profit/(Loss) for the period (5 -6)</b>	<b>767.99</b>	<b>235.73</b>	<b>274.48</b>	<b>1,470.94</b>	<b>892.53</b>
8	A (i) Items that will not be reclassified to profit or loss (net of tax) (ii) Income Tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (net of tax) (ii) Income Tax relating to items that will be reclassified to profit or loss					
9	<b>Total Comprehensive Income, net of tax (7 + 8)</b>	<b>767.99</b>	<b>235.73</b>	<b>274.48</b>	<b>1,470.94</b>	<b>892.53</b>
10	Paid up equity share capital (Face Value of Rs.10/- each)	4223.12	1,078.55	984.56	4223.12	984.56
11	Earning per share (of Rs.10/-each)					
	(a) Basic	2.039	2.189	2.802	8.622	9.080
	(b) Diluted	1.947	1.738	1.765	7.811	8.043
<b>See accompanying notes to the Audited Consolidated Financial results</b>						

//By the order of the Board//  
For Astal Laboratories Limited

Place: Hyderabad  
Date: 30/05/2026



*Sudheer Karna*

**SUDHEER KARNA KANKANALA**  
(Wholetime Director)  
DIN: 07591466

**NOTES TO AUDITED CONSOLIDATED FINANCIAL RESULTS:**

1	The above Audited Consolidated Financial Results of the company for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 30 <sup>th</sup> May, 2026.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6	The Company has opted to publish the financial result. The Consolidated results of the company will be available on the company's website <a href="https://astallabs.com/">https://astallabs.com/</a>

//By the order of the Board//  
For Astal Laboratories Limited

Place: Hyderabad  
Date: 30/05/2026



**SUDHEER KARNA KANKANALA**  
(Wholetime Director)  
DIN: 07591466

**STATEMENT OF AUDITED CONSOLIDATED ASSETS AND LIABILITIES AS AT  
MARCH 31, 2026**

(Rs. In lakhs.)

PARTICULARS		As at 31- March 2026	As at 31-March 2025
		(Audited)	(Audited)
<b>ASSETS</b>			
<b>1</b>	<b>Non - current assets</b>		
(a)	Property, plant and equipment	6,371.10	1,144.43
(b)	Right-of-use-asset	74.85	-
(c)	Investment property	-	-
(d)	Intangible assets - Good will consolidation	20,320.17	-
(e)	Financial assets	-	-
	(i) Investments	-	-
	(ii) Loans	409.26	409.25
	(iii) Balance With Banks	283.74	206.46
(f)	Deferred tax Assets (Net)	-	-
(g)	Other Non-current assets	10.53	10.00
	<b>Total non-current assets</b>	<b>27,469.64</b>	<b>1,770.15</b>
<b>2</b>	<b>Current assets</b>		
(a)	Inventories	6,752.31	1,475.98
(b)	<b>Financial assets</b>		
	(i) Investments		
	(ii) Trade receivables	15,634.73	2,766.41
	(iii) Cash and cash equivalents	130.11	173.00
	(iv) Other balances with banks	-	-
	(v) Loans	-	-
	(vi) Other financial assets	29.14	-
(c)	Other Current assests	1,803.54	148.53
	<b>Total current assets</b>	<b>24,349.84</b>	<b>4,563.92</b>
	<b>TOTAL ASSETS</b>	<b>51,819.48</b>	<b>6,334.06</b>
<b>EQUITY AND LIABILITIES</b>			
<b>1</b>	<b>Equity</b>		
(a)	Share capital	4,223.12	984.56
(b)	Other equity	29,152.53	2,614.91
	<b>Total Equity</b>	<b>33,375.64</b>	<b>3,599.47</b>
<b>2</b>	<b>Non-current liabilities</b>		
(a)	Financial liabilities		
	(i) Long-term borrowings	1,864.15	45.61
	(ii) Deferred tax liabilities (net)	86.23	11.86
	(iii) Lease Liabilities	64.78	-
(b)	Provisions		-

*Signature*





**Astral Laboratories Limited**

# **ASTAL LABORATORIES LIMITED**

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: <https://astallabs.com/>

(c)	Other Non Current liabilities	-	-
	<b>Total non-current liabilities</b>	<b>2,015.16</b>	<b>57.47</b>
<b>3</b>	<b>Current liabilities</b>		
(a)	Financial liabilities		
	(i) Borrowings	3,044.18	1,281.21
	(ii) Trade payables	12,380.47	1,077.49
	(iii) Lease Liabilities	16.21	-
(b)	Provisions	-	-
(c)	Other current Liabilities	987.80	318.42
	<b>Total current liabilities</b>	<b>16,428.66</b>	<b>2,677.12</b>
	<b>Total Liabilities</b>	<b>18,443.82</b>	<b>2,734.59</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>51,819.47</b>	<b>6,334.06</b>

//By the order of the Board//  
For Astal Laboratories Limited

Place: Hyderabad  
Date: 30/05/2026



**SUDHEER KARNA KANKANALA**  
(Wholetime Director)  
DIN: 07591466



Astal Laboratories Limited

# ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 I Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com; Mob. No: 6302730973, Website: https://astallabs.com/

## STATEMENT OF AUDITED CONSOLIDATED CASH FLOW FOR THE YEAR ENDED 31 MARCH 2026

(Rs. In Lakhs)

PARTICULARS	2025-26	2024-25
	Consolidation	Consolidation
<b>A) CASH FLOW FROM OPERATING ACTIVITIES</b>		
<b>Profit before tax for the year</b>		
Net Profit before exceptional and tax as Statement Profit & Loss (Increase in Reserves)	1,773.03	1,197.75
Adjusted for :-	-	-
Finance Cost	203.25	70.07
Depreciation and amortisation	122.82	22.31
Bad debts written off	-	-
Loss on sale/scrapping of Property, Plant and Equipments	-	-
Finance Cost	-	-
Interest income	(22.15)	(12.51)
<b>Operating Profit before Working Capital Changes</b>	<b>2076.95</b>	<b>1,277.63</b>
Adjusted for changes in working capital	-	-
Increase /(Decrease) in Trade Payables	4,534.52	-74.03
Increase /(Decrease) in Borrowings	-	-
Increase /(Decrease) in Other financial liabilities	-	-
Increase /(Decrease) in Other current liabilities	332.79	-89.46
Increase /(Decrease) in Other Non-current liabilities	-	-
Increase /(Decrease) in Provisions (except IT)	-	-
Increase /(Decrease) in Current Tax Liabilities (Net)	-	-
(Increase)/Decrease in Inventory	-588.56	-1,370.22
(Increase)/Decrease in Trade receivables	-7,934.07	-1,184.90
(Increase)/Decrease in Others current financial assets	-29.14	-
(Increase)/Decrease in Other current assets	1,353.23	229.38
(Increase) / Decrease in Non-current Financial Assets	-	-10.00
Consolidation adjustment	-1,413.52	-
<b>Cash Generated From Operations</b>	<b>(1,667.80)</b>	<b>(1,221.60)</b>
<b>Net Cash used in Operating Activities Before Extraordinary Items</b>	-	-
Less: - Extraordinary Items	-	-
<b>Cash Generated From Operations</b>	<b>(1,667.80)</b>	<b>(1,221.60)</b>
Less: - Taxes Paid	(102.08)	(30.13)
<b>Net Cash Flow/(used)From Operating Activates (A)</b>	<b>(1,769.88)</b>	<b>(1,251.73)</b>
<b>B) CASH FLOW FROM INVESTING ACTIVITIES</b>		
(Increase) / Decrease in Other Non-Current assets	10.00	(10.00)
Purchase of Fixed Assets	(139.26)	(577.50)
Investment in Sriven Pharma-Cash Consideration	-29.63	-
Deposits with Bank	(77.28)	(206.46)
Interest income	19.16	12.51
Proceeds From Sales/written off of Fixed Assets	-	-

*Handwritten signature*





**Astal Laboratories Limited**

**ASTAL LABORATORIES LIMITED**

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina

Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com; Mob. No: 6302730973, Website: <https://astallabs.com/>


	Net Cash Flow/(used) in Investing Activities (B)	(217.01)	(781.44)
<b>C)</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>	-	-
	Procurement of Borrowings	-	31.67
	Lease Liability	(22.34)	-
	Repayment of Borrowings	(143.34)	(5.47)
	Interest paid	(194.29)	(70.07)
	Shares/Warrents Amount Received	617.98	372.99
	<b>Net Cash Flow/(used) From Financing Activities C)</b>	<b>258.01</b>	<b>329.12</b>
	<b>Net Increase/(Decrease) in Cash and Cash Equivalent (A+B+C)</b>	<b>(1,728.88)</b>	<b>(1,704.05)</b>
	Opening balance of Cash and Cash Equivalent	-1,096.40	607.65
	Cash on hand	0.02	0.03
	Balance With Banks	172.99	607.61
	Bank overdrafts and cash credit facility (secured)*	-1,269.40	-
		-	-
	<b>Closing balance of Cash and Cash Equivalent</b>	<b>-2,825.28</b>	<b>(1,096.40)</b>
	Cash on hand	7.63	0.02
	Balance With Banks	62.63	172.99
	Bank overdrafts and cash credit facility (secured)*	(2,895.55)	-1,269.40

**Notes to Consolidated Audited Cash flow statement**

- Figures in brackets represent cash out flows.
- The above Cash Flow statement has been prepared under the "Indirect Method" set out in Accounting Standard (Ind AS-7) on Statement of Cash flows issued by the Institute of Chartered Accountants of India.
- Previous year's comparative have been reclassified to conform with current year's presentation wherever applicable.
- Bank overdrafts and cash credit facility are part of cash management system of the Company. Hence, considered as part of cash and cash equivalents

Place: Hyderabad  
Date: 30/05/2026

//By the order of the Board//  
For Astal Laboratories Limited




**SUDHEER KARNA KANKANALA**  
(Wholetime Director)  
DIN: 07591466